PUT - SPRINTER OPEN END - EDWARDS LIFESCIENCES | Real-time Boerse Frankfurt Warrants 10:54:17 2024-07-01 EDT | ||
| 0.28 EUR | +51.35% |
|
| 1 month | -75.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 0.28 | +51.35% |
| 24-06-28 | 0.185 | +23.33% |
| 24-06-27 | 0.15 | -53.12% |
| 24-06-26 | 0.32 | -21.95% |
| 24-06-25 | 0.41 | +5.13% |
Real-time Boerse Frankfurt Warrants
Last update July 01, 2024 at 10:54 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Vontobel
|
| WKN | VD3G52 |
| ISIN | DE000VD3G523 |
| Date issued | 2024-04-05 |
| Strike | 94.69 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.29 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.93 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.01 € |
| Spread % | 2.50% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
92.37
USD
Average target price
96.05
USD
Spread / Average Target
+3.99%
- Stock Market
- Certificates
- Certificat
